{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:03:33Z","timestamp":1787501013414,"version":"build-2736575974"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.radonc.2025.111072","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T07:29:20Z","timestamp":1754378960000},"page":"111072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Predictors of toxicities and oncological outcomes following postoperative ablative radiotherapy (POPART) for biochemical recurrence"],"prefix":"10.1016","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0319-599X","authenticated-orcid":false,"given":"Federica","family":"Ferrario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suela","family":"Vukcaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9584-637X","authenticated-orcid":false,"given":"Valeria","family":"Faccenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Chissotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3867-2844","authenticated-orcid":false,"given":"Riccardo Ray","family":"Colciago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0735-8621","authenticated-orcid":false,"given":"Roberta","family":"Muni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Di Cristina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"De Sanctis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rossano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4105-9493","authenticated-orcid":false,"given":"Stefano","family":"Andreoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Parabicoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luca","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Crespi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8309-924X","authenticated-orcid":false,"given":"Denis","family":"Panizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Roscigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Filippo","family":"Da Pozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Magli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8777-5997","authenticated-orcid":false,"given":"Maurizio","family":"Portaluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Arcangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111072_b0005","first-page":"14","article-title":"Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions","volume":"11","author":"Paller","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.radonc.2025.111072_b0010","doi-asserted-by":"crossref","first-page":"8204","DOI":"10.1200\/JCO.2005.03.1575","article-title":"Parameters for treatment decisions for salvage radiation therapy","volume":"23","author":"Hayes","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111072_b0015","doi-asserted-by":"crossref","unstructured":"Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans K, Collette L; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012 Dec 8;380(9858):2018-27. doi: 10.1016\/S0140-6736(12)61253-7. Epub 2012 Oct 19. PMID: 23084481.","DOI":"10.1016\/S0140-6736(12)61253-7"},{"key":"10.1016\/j.radonc.2025.111072_b0020","doi-asserted-by":"crossref","unstructured":"Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009 Mar;181(3):956-62. doi: 10.1016\/j.juro.2008.11.032. Epub 2009 Jan 23. PMID: 19167731; PMCID: PMC3510761.","DOI":"10.1016\/j.juro.2008.11.032"},{"key":"10.1016\/j.radonc.2025.111072_b0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02\/AUO AP 09\/95 trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.111072_b0030","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2023.05.038","article-title":"EAU-YAU Prostate Cancer Working Group. European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-a Multicenter Study","volume":"85","author":"Preisser","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.111072_b0035","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0025-6196(11)62406-3","article-title":"PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer","volume":"76","author":"Roberts","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.radonc.2025.111072_b0040","unstructured":"Linee guida carcinoma della prostata - AIOM - https:\/\/www.aiom.it\/linee-guida-aiom-2024-carcinoma-della-prostata."},{"key":"10.1016\/j.radonc.2025.111072_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110690","article-title":"Post-prostatectomy radiation therapy: Updated guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group (FROGG)","author":"Warrender-Sparkes","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111072_b0050","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jamaoncol.2020.2832","article-title":"Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in patients with Prostate Cancer: a Systematic Review","volume":"6","author":"Sachdev","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.111072_b0055","doi-asserted-by":"crossref","unstructured":"Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, Sargos P, Sydes MR, Brawley C, Brihoum M, Brown C, Chabaud S, Cook A, Forcat S, Fraser-Browne C, Latorzeff I, Parmar MKB, Tierney JF; ARTISTIC Meta-analysis Group. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020 Oct 31;396(10260):1422-1431. doi: 10.1016\/S0140-6736(20)31952-8. Epub 2020 Sep 28. PMID: 33002431; PMCID: PMC7611137.","DOI":"10.1016\/S0140-6736(20)31952-8"},{"key":"10.1016\/j.radonc.2025.111072_b0060","doi-asserted-by":"crossref","unstructured":"Parker CC, Petersen PM, Cook AD, Clarke NW, Catton C, Cross WR, Kynaston H, Parulekar WR, Persad RA, Saad F, Bower L, Durkan GC, Logue J, Maniatis C, Noor D, Payne H, Anderson J, Bahl AK, Bashir F, Bottomley DM, Brasso K, Capaldi L, Chung C, Cooke PW, Donohue JF, Eddy B, Heath CM, Henderson A, Henry A, Jaganathan R, Jakobsen H, James ND, Joseph J, Lees K, Lester J, Lindberg H, Makar A, Morris SL, Oommen N, Ostler P, Owen L, Patel P, Pope A, Popert R, Raman R, Ramani V, R\u00f8der A, Sayers I, Simms M, Srinivasan V, Sundaram S, Tarver KL, Tran A, Wells P, Wilson J, Zarkar AM, Parmar MKB, Sydes MR; RADICALS investigators. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). Ann Oncol. 2024 Jul;35(7):656-666. doi: 10.1016\/j.annonc.2024.03.010. Epub 2024 Apr 5. PMID: 38583574; PMCID: PMC7617161.","DOI":"10.1016\/j.annonc.2024.03.010"},{"key":"10.1016\/j.radonc.2025.111072_b0065","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111072_b0070","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111072_b0075","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2022.10.024","article-title":"Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for men with newly Diagnosed or Biochemically Recurrent Prostate Cancer","volume":"83","author":"Bukavina","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.111072_b0080","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijrobp.2011.10.069","article-title":"The timing of salvage radiotherapy after radical prostatectomy: a systematic review","volume":"84","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111072_b0085","doi-asserted-by":"crossref","unstructured":"Pahlajani N, Ruth KJ, Buyyounouski MK, Chen DY, Horwitz EM, Hanks GE, Price RA, Pollack A. Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1949-56. doi: 10.1016\/j.ijrobp.2011.04.005. Epub 2011 Jul 15. PMID: 21763081; PMCID: PMC3827957.","DOI":"10.1016\/j.ijrobp.2011.04.005"},{"key":"10.1016\/j.radonc.2025.111072_b0090","doi-asserted-by":"crossref","unstructured":"Hennequin C, Sargos P, Roca L, Silva M, Latorzeff I, Peiffert D, Cozzi S, Benyoucef A, Hasbini A, Supiot S, Ronchin P, Wachter T, Azria D, Cailleux PE, Cormier L, Zibouche M, Pign\u00e9 G. Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial. JCO 42, LBA259-LBA259(2024). Doi: 10.1200\/JCO.2024.42.4_suppl.LBA259.","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA259"},{"key":"10.1016\/j.radonc.2025.111072_b0095","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.eururo.2021.05.033","article-title":"Swiss Group for Clinical Cancer Research (SAKK). Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer after Prostatectomy: the SAKK 09\/10 Randomized phase 3 Trial","volume":"80","author":"Ghadjar","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.111072_b0100","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijrobp.2019.09.047","article-title":"Toxicity and Biochemical Outcomes of Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: results of a Randomized phase III Trial","volume":"106","author":"Qi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111072_b0105","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0360-3016(01)02664-5","article-title":"Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha\/beta ratio), similar to late-responding normal tissue","volume":"52","author":"Brenner","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111072_b0110","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","article-title":"Is alpha\/beta for prostate tumors really low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111072_b0115","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111072_b0120","doi-asserted-by":"crossref","unstructured":"Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2 = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e17-doi: 10.1016\/j.ijrobp.2010.10.075. Epub 2011 Feb 15. PMID: 21324610.","DOI":"10.1016\/j.ijrobp.2010.10.075"},{"key":"10.1016\/j.radonc.2025.111072_b0125","series-title":"Basic clinical radiobiology","author":"Steel","year":"2003"},{"key":"10.1016\/j.radonc.2025.111072_b0130","first-page":"6165","article-title":"Patient costs associated with external beam radiotherapy treatment for localized prostate cancer: the benefits of hypofractionated over conventionally fractionated radiotherapy","volume":"19","author":"Sethukavalan","year":"2012","journal-title":"Can J Urol"},{"key":"10.1016\/j.radonc.2025.111072_b0135","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.eururo.2024.08.030","article-title":"Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: results of the PACE-A Randomised Trial","volume":"86","author":"van As","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.111072_b0140","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.111072_b0145","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial","volume":"22","author":"Fransson","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111072_b0150","unstructured":"NCCN Clinical Practice Guidelines in Oncology Prostate Cancer Version 1.2025 - https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"10.1016\/j.radonc.2025.111072_b0155","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/jamaoncol.2023.7291","article-title":"Noninferiority of Hypofractionated vs conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: the NRG-GU003 phase 3 Randomized Clinical Trial","volume":"10","author":"Buyyounouski","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.111072_b0160","doi-asserted-by":"crossref","unstructured":"Ballas LK, Luo C, Chung E, Kishan AU, Shuryak I, Quinn DI, Dorff T, Jhimlee S, Chiu R, Abreu A, Jennelle R, Aron M, Groshen S. Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy. Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):50-60. doi: 10.1016\/j.ijrobp.2018.12.047. Epub 2018 Dec 31. PMID: 30605751; PMCID: PMC7457432.","DOI":"10.1016\/j.ijrobp.2018.12.047"},{"key":"10.1016\/j.radonc.2025.111072_b0165","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijrobp.2019.11.005","article-title":"Stereotactic Body Radiation Therapy to the Prostate Bed: results of a phase 1 Dose-Escalation Trial","volume":"106","author":"Sampath","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111072_b0170","doi-asserted-by":"crossref","unstructured":"Ma TM, Ballas LK, Wilhalme H, Sachdeva A, Chong N, Sharma S, Yang T, Basehart V, Reiter RE, Saigal C, Chamie K, Litwin MS, Rettig MB, Nickols NG, Yoon SM, Smith L, Gao Y, Steinberg ML, Cao M, Kishan AU. Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2023 Jan 1;115(1):142-152. doi: 10.1016\/j.ijrobp.2022.08.041. Epub 2022 Aug 23. PMID: 36007724; PMCID: PMC11386273.","DOI":"10.1016\/j.ijrobp.2022.08.041"},{"key":"10.1016\/j.radonc.2025.111072_b0175","doi-asserted-by":"crossref","unstructured":"Nagar H, Diven MA, Rippon B, Barbieri CE, Hu JC, Scherr DS, Yadav P, Tshering L, Chandrasekhar S, Wolfe S, Pennell R, Coonce M, Chen SL, Formenti SC, Strong P, Davicioni E, Molina AM, Nanus DM, Nauseef JT, Sternberg CN, Zhou XK, Lei W, Osborne JR, Marciscano AE, Tagawa ST. A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution. Eur Urol Oncol. 2025 Jun 9:S2588-9311(25)00152-X. doi: 10.1016\/j.euo.2025.05.014. Epub ahead of print. PMID: 40494733.","DOI":"10.1016\/j.euo.2025.05.014"},{"key":"10.1016\/j.radonc.2025.111072_b0180","doi-asserted-by":"crossref","first-page":"9349","DOI":"10.3390\/curroncol29120733","article-title":"Acute Toxicity and Quality of Life in a Post-Prostatectomy Ablative Radiation Therapy (POPART) Multicentric Trial","volume":"29","author":"Lucchini","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.radonc.2025.111072_b0185","article-title":"Toxicity profile and Patient-Reported outcomes following salvage Stereotactic Ablative Radiation Therapy to the prostate Bed: the POPART multicentric prospective study","volume":"25","author":"Ferrario","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111072_b0190","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ijrobp.2020.11.010","article-title":"Prostate Bed Delineation guidelines for Postoperative Radiation Therapy: on Behalf of the Francophone Group of Urological Radiation Therapy","volume":"109","author":"Robin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111072_b0195","unstructured":"National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 - https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"10.1016\/j.radonc.2025.111072_b0200","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/nau.23907","article-title":"Evaluating urinary incontinence before and after radical prostatectomy using the international consultation on incontinence questionnaire-short form","volume":"38","author":"Machioka","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.radonc.2025.111072_b0205","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/19317611.2021.1936333","article-title":"Post-Radical Prostatectomy Erectile Dysfunction Assessed using the IIEF-5 Questionnaire - a Systematic Literature Review","volume":"34","author":"Jurys","year":"2021","journal-title":"Int J Sex Health"},{"key":"10.1016\/j.radonc.2025.111072_b0210","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.2021.39.6_suppl.214","volume":"39","author":"Parzen","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2025.111072_b0215","doi-asserted-by":"crossref","unstructured":"Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, Wei JT; PROSTQA Consortium. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology. 2015 Jan;85(1):101-5. doi: 10.1016\/j.urology.2014.08.044. PMID: 25530370; PMCID: PMC4274392.","DOI":"10.1016\/j.urology.2014.08.044"},{"key":"10.1016\/j.radonc.2025.111072_b0220","doi-asserted-by":"crossref","unstructured":"Chipman JJ, Sanda MG, Dunn RL, Wei JT, Litwin MS, Crociani CM, Regan MM, Chang P; PROST-QA Consortium. Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. J Urol. 2014 Mar;191(3):638-45. doi: 10.1016\/j.juro.2013.09.040. Epub 2013 Sep 25. PMID: 24076307; PMCID: PMC5006995.","DOI":"10.1016\/j.juro.2013.09.040"},{"key":"10.1016\/j.radonc.2025.111072_b0225","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3390\/cancers14030696","article-title":"Stereotactic Radiotherapy after Radical Prostatectomy in patients with Prostate Cancer in the Adjuvant or Salvage setting: a Systematic Review","volume":"14","author":"Schr\u00f6der","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111072_b0230","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.eururo.2014.06.012","article-title":"Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients","volume":"66","author":"Cozzarini","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.111072_b0235","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.ijrobp.2009.04.094","article-title":"Radiation dose-volume effects and the penile bulb","volume":"76","author":"Roach","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111072_b0240","article-title":"ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer","volume":"9","author":"Dal Pra","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111072_b0245","doi-asserted-by":"crossref","unstructured":"Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, M\u00e9nard C. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):361-8. doi: 10.1016\/j.ijrobp.2009.02.006. Epub 2009 Apr 23. PMID: 19394158; PMCID: PMC2847420.","DOI":"10.1016\/j.ijrobp.2009.02.006"},{"key":"10.1016\/j.radonc.2025.111072_b0250","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ijrobp.2007.04.068","article-title":"Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy","volume":"69","author":"Wiltshire","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111072_b0255","doi-asserted-by":"crossref","unstructured":"Nikitas J, Jamshidian P, Tree AC, Hall E, Dearnaley D, Michalski JM, Lee WR, Nguyen PL, Sandler HM, Catton CN, Lukka HR, Incrocci L, Heemsbergen W, Pos FJ, Roy S, Malone S, Horwitz E, Wong JK, Arcangeli S, Sanguineti G, Romero T, Sun Y, Steinberg ML, Valle LF, Weidhaas JB, Spratt D, Telesca D, Kishan AU. The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials. Lancet Oncol. 2025 Jan 30:S1470-2045(24)00720-4. doi: 10.1016\/S1470-2045(24)00720-4. Epub ahead of print. PMID: 39894025.","DOI":"10.1016\/S1470-2045(24)00720-4"},{"key":"10.1016\/j.radonc.2025.111072_b0260","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.21037\/qims-21-697","article-title":"A narrative review of MRI acquisition for MR-guided-radiotherapy in prostate cancer","volume":"12","author":"Yuan","year":"2022","journal-title":"Quant Imaging Med Surg"},{"key":"10.1016\/j.radonc.2025.111072_b0265","doi-asserted-by":"crossref","unstructured":"Nikitas J, Ballas LK, Romero T, Lynch C, Ma TM, Valle LF, Sachdeva A, Chong N, Basehart V, Franco A, Reiter R, Saigal C, Chamie K, Litwin MS, Donin NM, Rettig M, Nickols NG, Cao M, Liauw SL, Steinberg ML, Kishan AU. Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial. JAMA Oncol. 2025 May 15:e251059. doi: 10.1001\/jamaoncol.2025.1059. Epub ahead of print. PMID: 40372727; PMCID: PMC12082483.","DOI":"10.1001\/jamaoncol.2025.1059"},{"key":"10.1016\/j.radonc.2025.111072_b0270","doi-asserted-by":"crossref","unstructured":"Montero A, Hernando O, L\u00f3pez M, Valero J, Ci\u00e9rvide R, S\u00e1nchez E, Prado A, Zobec HB, Chen-Zhao X, \u00c1lvarez B, Garc\u00eda-Aranda M, Alonso L, Alonso R, Fern\u00e1ndez-Let\u00f3n P, Rubio C. SABR tolerance after prostatectomy: pushing the boundaries of ultrahypofractionation. Clin Transl Oncol. 2025 Jan 25. doi: 10.1007\/s12094-025-03845-w. Epub ahead of print. PMID: 39862341.","DOI":"10.1007\/s12094-025-03845-w"},{"key":"10.1016\/j.radonc.2025.111072_b0275","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.111072_b0280","unstructured":"Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial. Lancet. 2024 Jun 1;403(10442):2405-2415. doi: 10.1016\/S0140-6736(24)00548-8. Epub 2024 May 16. PMID: 38763154; PMCID: PMC7616360."},{"key":"10.1016\/j.radonc.2025.111072_b0285","doi-asserted-by":"crossref","unstructured":"Murthy V, Mallick I, Maitre P, Mulye G, Arunsingh M, Valle L, Steinberg M, Kennedy T, Loblaw A, Kishan AU. Pelvic regional control with 25Gy in 5 fractions in SBRT for high risk prostate cancer: Pooled prospective outcomes from the SHARP consortium. Int J Radiat Oncol Biol Phys. 2025 Jan 2:S0360-3016(24)03773-8. doi: 10.1016\/j.ijrobp.2024.12.018. Epub ahead of print. PMID: 39755216.","DOI":"10.1016\/j.ijrobp.2024.12.018"},{"key":"10.1016\/j.radonc.2025.111072_b0290","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ijrobp.2016.08.043","article-title":"Salvage Radiation Therapy Dose Response for Biochemical failure of Prostate Cancer after Prostatectomy-a Multi-Institutional Observational Study","volume":"96","author":"Pisansky","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111072_b0295","doi-asserted-by":"crossref","unstructured":"Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker PD, Roobol MJ. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. BJU Int. 2020 Feb;125(2):206-214. doi: 10.1111\/bju.14944. Epub 2019 Nov 29. PMID: 31680398; PMCID: PMC7383738.","DOI":"10.1111\/bju.14944"},{"key":"10.1016\/j.radonc.2025.111072_b0300","author":"Mazzone","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.111072_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110476","article-title":"Undetectable PSA predicts outcome after salvage radiotherapy for biochemical recurrence following radical prostatectomy","volume":"200","author":"Scharl","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111072_b0310","doi-asserted-by":"crossref","unstructured":"Burdett S, Fisher DJ, Tierney JF, Cook AD, Spratt DE, Dignam JJ, Seiferheld WF, Kishan AU, Sun Y, Chabaud S, Efstathiou JA, Parker CC, Pollack A, Sargos P, Latorzeff I, Brihoum M, Catton CN, Clarke NW, Feng FY, Karrison TG, Pommier P, Sandler HM, Sydes MR, Vale CL; DADSPORT Meta-analysis Collaboration. Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data. Eur Urol. 2025 Jun 25:S0302-2838(25)00291-X. doi: 10.1016\/j.eururo.2025.05.013. Epub ahead of print. PMID: 40571441.","DOI":"10.1016\/j.eururo.2025.05.013"},{"key":"10.1016\/j.radonc.2025.111072_b0315","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.annonc.2022.05.007","article-title":"Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09\/10 randomized clinical trial","volume":"33","author":"Dal Pra","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.111072_b0320","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"EMBARK Study improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025045761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025045761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:02:10Z","timestamp":1759521730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025045761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":64,"alternative-id":["S0167814025045761"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111072","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of toxicities and oncological outcomes following postoperative ablative radiotherapy (POPART) for biochemical recurrence","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111072"}}